Printer Friendly

CYTRX CORPORATION ANNOUNCES PHASE II TRIALS OF RHEOTHRX(R) INJECTION FOR SICKLE CELL

CYTRX CORPORATION ANNOUNCES PHASE II TRIALS OF RHEOTHRX(R) INJECTION
 FOR SICKLE CELL
 NORCROSS, Ga., July 20 /PRNewswire/ -- CytRx Corporation (NASDAQ-NMS: CYTR) announced today the enrollment of the first patient in a phase II trial investigating the safety and efficacy of RheothRx(R) Injection in sickle cell crisis.
 The trial is part of a multi-center study under the direction of Burroughs Wellcome Co., Research Triangle Park, N.C., who has licensed the worldwide rights to RheothRx(R) Injection from CytRx.
 Jack Luchese, president and CEO of CytRx, said: "This is an important event for CytRx as it marks the beginning of development of a second indication in the United States for this rheologic agent. RheothRx(R) Injection has been in phase II clinical studies for heart attack patients since March of 1992." Luchese also added, "RheothRx(R) Injection has demonstrated exciting effects in experimental models involving sickle red cells, and we are optimistic that it will prove to be of benefit in this disease for which there is currently no cure or satisfactory treatment."
 CytRx Corporation is a biopharmaceutical company engaged in the research and development of therapeutics incorporating copolymers. The company is developing human pharmaceutical products intended for use in the treatment of vascular, immune system and infectious diseases as well as burns.
 Burroughs Wellcome Co. is a research-based pharmaceutical company with headquarters in Research Triangle Park, N.C. The company is a wholly owned subsidiary of The Wellcome Foundation Ltd. of London.
 -0- 7/20/92
 /CONTACT: CytRx public relations, 404-368-9500/
 (CYTR) CO: CytRx Corporation; Burroughs Wellcome Company ST: Georgia, North Carolina IN: MTC SU:


EA-BN -- AT015 -- 0736 07/20/92 12:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1992
Words:276
Previous Article:LOAN AMERICA EARNS RECORD $1.4 MILLION IN SECOND QUARTER; MORTGAGE BANKER'S NET IS UP 172 PERCENT ABOVE SAME PERIOD A YEAR AGO
Next Article:UNITED WATER RESOURCES REPORTS HIGHER SIX-MONTH EARNINGS DESPITE A SECOND QUARTER DIP
Topics:


Related Articles
CYTRX CORPORATION ANNOUNCES THE BEGINNING OF PHASE II TRIALS OF RHEOTHRX(R) INJECTION
CYTRX CORPORATION ANNOUNCES PHASE II TRIALS OF RHEOTHRX(R) INJECTION FOR SICKLE CELL
CYTRX CORPORATION ANNOUNCES PATIENT ENROLLMENT FOR NEW RHEOTHRX(R) INJECTION CLINICAL TRIAL
FIRST OF TWO RHEOTHRX(R) STUDIES REPORTED: 9,000-PATIENT PHASE III STUDY IN ACUTE MYOCARDIAL INFARCTION PLANNED
CYTRX FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR MULTIPLE DRUG RESISTANT CANCER TREATMENT
CYTRX ANNOUNCES RHEOTHRX STEERING COMMITTEE RECOMMENDATION EXPECTED IN OCTOBER
CYTRX ANNOUNCES TERMINATION OF GLAXO WELLCOME RHEOTHRX DEVELOPMENT PROGRAM
CytRx Corporation Presents at BIO 1998 Investor and Partnering Conference
CytRx forms prostate cancer alliance with Cytogen and Progenics.
CYTRX CLINICAL TRIAL OF ARIMOCLOMOL FOR ALS SHOWS PROMISE.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters